Financial Data and Key Metrics Changes - Revenue for fiscal year 2024 totaled $28.34 million, an increase of 32.9% from fiscal year 2023 [2] - Adjusted EBITDA for fiscal year 2024 was $8.9 million, an 8.9% increase year over year [2][18] - Fourth quarter 2024 revenue increased by 59.2% to $9.1 million compared to $5.7 million in Q4 2023 [18] - Net income for fiscal year 2024 increased by 258% to $2.2 million, or $0.33 per diluted share [17] Business Line Data and Key Metrics Changes - Revenue from direct patient services segment was $12.6 million for fiscal year 2024, a 253% increase from $3.4 million in fiscal year 2023 [13][14] - Revenue from the equipment leasing segment decreased to $15.6 million from $17.8 million in fiscal year 2023 [14] - Gamma Knife revenue declined by 11.6% to $9.7 million for fiscal year 2024 [14] - Proton beam therapy revenue decreased by 1.8% to $10 million in fiscal year 2024 [15] Market Data and Key Metrics Changes - The company has established its first direct patient services cancer treatment centers in the U.S. with the acquisition of three centers in Rhode Island [11] - The international business segment is expected to see continued growth, particularly in Ecuador and the newly opened center in Puebla, Mexico [9][10] Company Strategy and Development Direction - The company is transitioning from a cancer treatment equipment leasing focus to a more patient-centric service model [1] - Strategic initiatives include expanding the footprint in Rhode Island and establishing new treatment centers in Mexico [10][11] - The company has received CON approval to build a fourth radiation therapy center and the first proton beam therapy center in Rhode Island [11][40] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth strategy and the ability to navigate industry challenges [39][40] - The recent acquisition and operational efficiencies are expected to enhance service quality and accessibility [39] - Management anticipates stronger international growth and increased treatment volumes in the coming years [10][12] Other Important Information - The company ended the year with cash and cash equivalents of $11.3 million, down from $13.8 million at the end of 2023 [25] - Shareholders' equity increased to $25.2 million, or $3.92 per outstanding share, compared to $22.6 million, or $3.59 per outstanding share, at the end of 2023 [25] Q&A Session Summary Question: Benefits of expanding footprint in Rhode Island - The expansion in Rhode Island is expected to create synergies with Brown University Health and other healthcare systems, enhancing cancer care provision [32][33]

Core Insights - American Shared Hospital Services reported strong financial results for FY 2024, with revenue reaching $28.34 million, a 32.9% increase year-over-year [3][8][7] - The company is transitioning from a traditional leasing model to a direct provider of radiation therapy services, which aligns with its long-term growth strategy [4][3] - The appointment of Gary Delanois as CEO marks a new phase of growth for the company, while Ray Stachowiak continues as Executive Chairman [5][3] Financial Performance - FY 2024 revenue from direct patient services surged by 253.4% to $12.56 million, while leasing segment revenue decreased by 12.1% to $15.63 million [8][7] - Net income attributable to the company increased by 258.4% to $2.19 million, translating to $0.34 per diluted share [12][8] - Adjusted EBITDA for FY 2024 rose by 8.5% to $8.89 million [13][7] Quarterly Results - In Q4 2024, revenue increased by 59.2% to $9.07 million, driven by expanded radiation therapy services [14][8] - Direct patient services revenue in Q4 2024 was $4.75 million, a 420.2% increase from the previous year [14][8] - Q4 2024 net income attributable to the company was a loss of $1.31 million, compared to a profit of $0.42 million in Q4 2023 [16][8] Operational Highlights - The company has successfully integrated new facilities in Rhode Island and Puebla, Mexico, contributing to revenue growth [3][8] - Gross margin for FY 2024 was $9.19 million, slightly down from $9.34 million in FY 2023 due to higher operating costs in the direct patient services segment [10][8] - The company is focused on improving operational efficiencies and expanding health system partnerships to drive future growth [3][4] Balance Sheet - As of December 31, 2024, cash and cash equivalents totaled $11.28 million, down from $13.81 million a year earlier [19][8] - Shareholders' equity increased to $25.18 million, or $3.92 per outstanding share, compared to $22.62 million, or $3.59 per share, at the end of 2023 [19][8]

Core Insights - American Shared Hospital Services reported a strong revenue growth of 32.9% for FY 2024, reaching $28.34 million compared to $21.33 million in FY 2023, driven by strategic expansions and operational efficiencies [4][6][8] - The company has transitioned from a traditional leasing model to a direct provider of radiation therapy services, which aligns with its long-term growth strategy focused on increasing patient volumes [3][4][8] - Gary Delanois has been appointed as the new CEO, indicating a shift in leadership as the company enters a new growth phase [3][4] Financial Performance - For FY 2024, revenue from direct patient services surged by 253.4% to $12.56 million, while leasing segment revenue decreased by 12.1% to $15.63 million [4][11] - Gross margin for FY 2024 was $9.19 million, slightly down from $9.34 million in FY 2023, primarily due to higher operating costs in the direct patient services segment [6][8] - Net income attributable to the company increased by 258.4% to $2.19 million, or $0.34 per diluted share, compared to $0.10 per diluted share in FY 2023 [8][10] Quarterly Highlights - In Q4 2024, revenue increased by 59.2% to $9.07 million compared to $5.70 million in Q4 2023, driven by expanded radiation therapy services [10][11] - Direct patient services revenue for Q4 2024 was $4.75 million, a significant increase of 420.2% from the same period last year [11][12] - Adjusted EBITDA for Q4 2024 rose by 29.3% to $3.46 million, compared to $2.68 million in Q4 2023 [14][27] Balance Sheet Overview - As of December 31, 2024, cash and cash equivalents totaled $11.28 million, down from $13.81 million a year earlier [15][25] - Shareholders' equity increased to $25.18 million, or $3.92 per outstanding share, compared to $22.62 million, or $3.59 per share at the end of 2023 [15][25] - Total assets grew to $60.20 million from $48.16 million in the previous year, reflecting the company's expansion efforts [25]

Core Points - American Shared Hospital Services (AMS) will hold a conference call on April 4, 2025, at 1:00 pm ET to discuss its fourth quarter and full year 2024 financial results [1] - A press release detailing the financial results will be issued before the market opens on the same day [1] Company Overview - AMS is a leading provider of turnkey solutions for cancer treatment centers, health systems, and large cancer networks in North and South America [3] - The company collaborates with partners to enhance cancer service lines and provide integrated care to patients locally [3] - AMS shares costs and profits with health system partners based on ownership interests [3]

Core Viewpoint - A-Mark Precious Metals, Inc. is expanding its presence in the collectible coin market through strategic acquisitions of Spectrum Group International, AMS Holding, and Pinehurst Coin Exchange, which are expected to enhance gross margins and customer base during periods of low bullion volatility [1][14]. Group 1: Acquisition Details - A-Mark acquired 100% of Spectrum Group International (SGI) for $92.0 million, consisting of $46.0 million in cash and $46.0 million in A-Mark stock valued at $27.51 per share [2][13]. - The company agreed to pay $50.0 million in cash for the remaining 90% of AMS Holding, with potential additional payments of up to $9.0 million based on performance benchmarks [3][13]. - A-Mark paid $6.5 million in cash to acquire 51% of Pinehurst's stock, with additional cash consideration of up to $5.3 million based on performance [4][13]. Group 2: Company Overviews - AMS Holding, founded in 1984, generated total revenue of $203.8 million and adjusted EBITDA of $9.3 million for the year ended December 31, 2024, serving over 500,000 customers [7][13]. - Pinehurst Coin Exchange, established in 2005, generated approximately $215.8 million in total revenue and $7.7 million in EBITDA for the year ended December 31, 2024, with nearly 300,000 customers [10][13]. - Spectrum Group International, parent of Stack's Bowers Galleries, generated total revenue of $536.4 million and EBITDA of $10.9 million for the fiscal year ended June 30, 2024 [13]. Group 3: Strategic Importance - The acquisitions are expected to bring several hundred thousand new customers into A-Mark's ecosystem and enhance gross margin profiles, particularly during periods of limited bullion market volatility [14][15]. - A-Mark's CEO emphasized the integration of the acquired businesses into A-Mark's global sourcing network and logistics platform, which is anticipated to create synergistic selling opportunities [15].

Core Viewpoint - The Brink's Company (BCO) is expected to experience growth accelerating to high-single-digit percentages, supported by solid adoption trends in the industry [1]. Group 1: Investment Approach - The investment strategy focuses on long-term investments while also incorporating short-term shorts to identify alpha opportunities [1]. - The analysis is based on a bottom-up approach, examining the fundamental strengths and weaknesses of individual companies [1]. - The investment duration is medium to long-term, aiming to identify companies with solid fundamentals, sustainable competitive advantages, and growth potential [1].

Core Viewpoint - American Shared Hospital Services (AMS) has received a Certificate of Need (CON) to establish a Proton Beam Radiation Treatment (PBRT) facility in Johnston, Rhode Island, enhancing local cancer care capabilities and reducing the need for patients to travel to other states for treatment [1][2][3]. Company Developments - AMS's subsidiary, ASHS - Rhode Island Proton Beam Radiation Therapy, LLC, will construct and operate the PBRT system, expected to treat its first patients within 36 to 39 months [3]. - The new facility will complement AMS's existing three photon radiation therapy facilities in Rhode Island, where AMS holds a 60% majority ownership [4]. - In April 2024, AMS's subsidiary received another CON for Bristol Radiation Therapy, LLC, further expanding its network of radiation therapy facilities in the region [4]. Market Position and Growth Potential - The establishment of the PBRT facility represents a significant growth opportunity for AMS, as there are currently only two operational Proton Beam Radiation Therapy Systems in the Northeast [5]. - The facility's strategic location between New York City and Boston is expected to improve access to advanced cancer treatment technologies for patients in the Northeast [5]. - AMS has recently strengthened its senior management team with experienced executives to support the development and operation of radiation therapy facilities [5]. Company Background - AMS has been operational for 40 years and has been publicly traded since 1984, providing financial and technological solutions to cancer treatment centers and hospitals globally [5]. - The company collaborates with major global Original Equipment Manufacturers (OEMs) to offer a range of radiation therapy technologies, including Proton Beam Radiation Therapy Systems and Gamma Knife products [5]. - AMS's strategic initiative to acquire majority equity interests in Rhode Island radiation therapy facilities marks a shift from being a technology supplier to a direct provider of cancer care [5].

Revenue and Growth - The Company recognized leasing revenue of approximately $3,312,000 and $11,464,000 for the three and nine-month periods ended September 30, 2024, compared to $3,946,000 and $12,987,000 for the same periods in the prior year, respectively [90]. - Retail revenues for the three and nine-month periods ended September 30, 2024 were approximately $3,687,000 and $7,807,000, compared to $988,000 and $2,440,000 for the same periods in the prior year [93]. - Revenues for the three and nine-month periods ended September 30, 2024 increased by $1,865,000 (36.4%) and $3,644,000 (23.3%) to $6,999,000 and $19,271,000, respectively, compared to the same periods in the prior year [99]. - Retail segment revenues increased by $2,699,000 (273.5%) and $5,367,000 (220.5%) to $3,687,000 and $7,807,000 for the three and nine-month periods ended September 30, 2024, primarily due to the RI Acquisition [99]. - Revenues from the PBRT system increased by $97,000 (4.4%) and $308,000 (4.4%) to $2,316,000 and $7,386,000 for the three and nine-month periods ended September 30, 2024, driven by higher volumes and a shift in payor mix [100]. - Gamma Knife revenue decreased by $895,000 (32.9%) and $1,218,000 (14.6%) to $1,821,000 and $7,131,000 for the three and nine-month periods ended September 30, 2024, due to lower procedure volumes [102]. Acquisitions and Investments - The Company acquired 60% of the equity interests of the RI Companies on May 7, 2024, which operate three radiation therapy facilities in Rhode Island [83]. - The Company recorded a net bargain purchase gain of $3,942,000 related to the RI Acquisition, which closed on May 7, 2024, after acquiring 60% of the equity interests of the RI Companies for $2,850,000 [114]. - As of September 30, 2024, the Company had commitments totaling $13,383,000 for the purchase and installation of four Leksell Gamma Knife Esprit Systems and two Linear Accelerator systems [128]. - The Supplemental Term Loan of $2,700,000 was added to the credit agreement to finance capital expenditures in Puebla, Mexico [122]. Financial Performance and Expenses - Total costs of revenue increased by $2,597,000 (85.6%) and $4,191,000 (46.0%) to $5,629,000 and $13,290,000 for the three and nine-month periods ended September 30, 2024 [106]. - Selling and administrative expenses increased by $188,000 (10.8%) and $436,000 (8.3%) to $1,923,000 and $5,698,000 for the three and nine-month periods ended September 30, 2024, due to higher personnel costs and legal fees [111]. - Interest expense increased by $59,000 (21.3%) and $245,000 (29.7%) to $336,000 and $1,070,000 for the three and nine-month periods ended September 30, 2024, attributed to higher borrowings and interest rates [113]. Cash and Debt Management - The Company had cash, cash equivalents, and restricted cash of $14,077,000 as of September 30, 2024, an increase of $269,000 from December 31, 2023 [119]. - Working capital decreased by $1,518,000 (15.6%) to $8,159,000 as of September 30, 2024, primarily due to increases in accounts payable and accrued liabilities [120]. - The Company has a combined long-term debt of $14,375,000 as of September 30, 2024 [126]. - The Company entered into a $22,000,000 credit agreement with Fifth Third Bank, which includes a $9,500,000 term loan, a $5,500,000 delayed draw term loan, and a $7,000,000 revolving line of credit [121]. - The Company borrowed $4,500,000 under the revolving line of credit as of September 30, 2024 [128]. - The Company is subject to covenants under the credit agreement, including a minimum fixed charge coverage ratio of 1.25 to 1.0 and a total funded debt to EBITDA ratio of 3.0 to 1.0 [123]. - The Company is in compliance with all debt covenants as of September 30, 2024 [125]. Regulatory and Market Conditions - The Centers for Medicare and Medicaid established a 2024 reimbursement rate of approximately $7,420 for a Medicare Gamma Knife treatment, down from $7,691 in 2023 [85]. - The approximate CMS reimbursement rates for PBRT treatments in 2024 are $561 for simple treatments and $1,362 for intermediate and complex treatments, compared to $572 and $1,323 in 2023, respectively [85]. Operational Overview - The Company operates ten domestic Gamma Knife units and one PBRT system in the United States as of September 30, 2024 [89]. - The Company has two international Gamma Knife units in operation in Lima, Peru, and Guayaquil, Ecuador, as part of its retail segment [89]. - The Company’s leasing contracts typically have a ten-year term and are classified as either fee per use or revenue sharing [90]. - The Company’s PBRT system at Orlando Health operates under a revenue share contract within the leasing segment [89]. Related Party Transactions - Total related party transactions for the three months ended September 30, 2024, amounted to $694,000, compared to $2,338,000 for the same period in 2023 [132]. - The Company has cash on hand of $14,077,000 as of September 30, 2024, and is actively seeking financing resources for future projects [128].

Financial Data and Key Metrics Changes - Revenue for Q3 2024 increased by 36% year-over-year to $6.99 million, up from $5.1 million in Q3 2023, driven by the Rhode Island acquisition and the new facility in Puebla, Mexico [14][31] - Gross margin decreased to $1.37 million from $2.10 million in Q3 2023, impacted by lower Gamma Knife treatment volumes and a shift in revenue mix [15][35] - The company reported a net loss of $207,000 or $0.03 per share for Q3 2024, compared to a net income of $118,000 or $0.02 per share in Q3 2023 [15][39] - Cash and equivalents at the end of Q3 2024 stood at over $14.1 million, approximately $2.17 per share [16][43] Business Line Data and Key Metrics Changes - Revenue from the Patient Services or Retail segment surged by 273% to $3.7 million in Q3 2024, primarily due to the Rhode Island acquisition and Puebla operations [32] - Medical Equipment Leasing revenue decreased by 16.1% to $3.31 million, attributed to lower Gamma Knife volumes [33] - Proton therapy revenue increased by 4.4% to $2.3 million, with a 5.4% rise in proton therapy fractions [34] Market Data and Key Metrics Changes - The international business is seen as a significant growth opportunity, with the only Gamma Knife systems in Peru and Ecuador, and a new center in Puebla, Mexico [24] - A joint venture for a Gamma Knife facility in Guadalajara, Mexico was announced, which will be one of only three in the country [25] Company Strategy and Development Direction - The company is focused on integrating the Rhode Island acquisition and optimizing operations, which includes investing in upgraded equipment and improving operational efficiencies [13][19] - Plans to expand geographically and diversify product offerings, including the addition of linear accelerators and a proton beam center in Rhode Island [69][70] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges such as seasonality, procedure volume fluctuations, and integration costs from the Rhode Island acquisition [13][26] - There is optimism about future growth, particularly from international operations and new business opportunities [29][73] Other Important Information - The company has incurred additional costs related to the Rhode Island acquisition, expected to decrease in Q4 2024 [26] - The bargain purchase gain from the Rhode Island acquisition was increased by $263,000 in Q3 2024 [38] Q&A Session Summary Question: Follow-up on start-up costs and ramp-up period for new centers - Management confirmed that costs related to the Rhode Island acquisition and integration are impacting results, and acknowledged a ramp-up period for new centers [46][47] Question: Performance of the Puebla facility - Management expressed satisfaction with the revenue growth from the Puebla facility since its opening [51] Question: Impact of outdated equipment on business - Management noted that replacing outdated equipment has led to increased patient referrals and volumes [55][56] Question: Marketing efforts for the Rhode Island centers - Management confirmed ongoing marketing efforts to raise awareness among referring physicians about the upgraded facilities [58][60] Question: Gamma Knife treatment volume issues - Management attributed the decline in Gamma Knife volumes to various factors, including physician vacations and equipment downtime, but expressed confidence in overcoming these challenges [61][62] Question: Concerns about stock performance and transparency - Management acknowledged shareholder frustrations and emphasized the long-term growth strategy, including geographic expansion and product diversification [68][70]

Revenue Performance - Total revenue for Q3 2024 was $6,999,000, representing a 36.3% increase compared to Q3 2023[2] - Revenue from direct patient services ("retail") segment reached $3,687,000, a significant increase of 273.2% year-over-year[3] - Revenue from medical equipment leasing segment was $3,312,000, reflecting a decrease of 16.1% compared to the prior year[4] - Proton beam radiation therapy revenue increased by 4.4% to $2,316,000, with treatments rising by 5.4%[11] - Gamma Knife revenue decreased by 32.9% to $1,821,000, with procedures down by 31.0%[12] - For the first nine months of 2024, total revenue increased by 23.3% to $19,271,000 compared to $15,627,000 in the same period of 2023[17] - Revenues for the three months ended September 30, 2024, were $6,999,000, a 36.4% increase from $5,134,000 for the same period in 2023[29] Profitability and Loss - Gross margin decreased to $1,370,000, with a gross margin percentage of 19.6%, down from 40.9% in the previous year[5] - Net loss for Q3 2024 was $207,000, or ($0.03) per diluted share, compared to net income of $118,000, or $0.02 per diluted share in Q3 2023[6] - Adjusted EBITDA for Q3 2024 was $1,366,000, down from $1,669,000 in Q3 2023[6] - Gross margin decreased to $1,370,000 for the three months ended September 30, 2024, compared to $2,102,000 in the prior year, reflecting a decline of 34.8%[29] - Adjusted EBITDA for the three months ended September 30, 2024, was $1,366,000, down 18.1% from $1,669,000 in the same period of 2023[30] - Net loss attributable to American Shared Hospital Services was $207,000 for the three months ended September 30, 2024, compared to a net income of $118,000 in the prior year[29] Financial Position - Cash at September 30, 2024, was $14,077,000, compared to $13,808,000 at December 31, 2023[21] - Total assets increased to $63,269,000 as of September 30, 2024, up from $48,162,000 at the end of 2023, representing a growth of 31.4%[29] - Current liabilities rose to $17,561,000 as of September 30, 2024, compared to $10,779,000 at the end of 2023, indicating a 62.5% increase[29] - Cash and cash equivalents increased to $14,077,000 as of September 30, 2024, compared to $13,808,000 at the end of 2023, a growth of 1.9%[29] Expenses - Selling and administrative expenses were $1,923,000 for the three months ended September 30, 2024, compared to $1,735,000 in the same period of 2023, an increase of 10.8%[29] - Interest expense for the three months ended September 30, 2024, was $336,000, up from $277,000 in the prior year, reflecting a rise of 21.3%[29] Other Financial Metrics - The company reported a bargain purchase gain of $263,000 for the three months ended September 30, 2024, compared to a gain of $0 in the same period of 2023[29]